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The True Incremental
Cost of ECG Screening:
The Price Is Not Right,
But the Cost Appears Effective
In their analysis of the economic impact of the Italian electrocar-
diography (ECG) screening program for competitive athletes (1),
Halkin et al. (2) concluded that the cost in the United States over
a 20-year period would range from $51 to $69 billion. Assuming
that the program would be expected to save 4,813 lives (1), they
alculated a cost per life saved of $10.6 to $14.4 million. However,
he methods and assumptions used significantly inflate the cost of
CG screening. First, while the title describes the cost of “ECG
creening,” the figures provided for history and physical range from
224 to $313/athlete/year, and the estimates for ECGs range from
39 to $47/athlete/year. Thus, the ECG represents just 15% to
8% of the combined price, while the history and physical,
urrently recommended by the American Heart Association (3)
omprise 75% of the total, even accounting for subsequent addi-
ional testing. Determining cost effectiveness of the ECG compo-
ent requires estimating the incremental cost and incremental
enefit of the ECG, which was not done. Next, while the paper’s
itle describes the “cost,” the figures used are actually “prices,”
hich may not reflect the true costs based on actual payments and
iscounts negotiated for large screening programs.
The authors also justify reporting “cost per life saved” rather than
he more common “cost per year of life saved” because the lifespan of
he individuals saved is uncertain. However, most patients with
ypertrophic cardiomyopathy, the most common cause of sudden
ardiac death (SCD) in the young, live normal or near-normal
ifespans (4), as do those with most of the conditions leading to SCD
n young athletes. Failure to adjust for estimated lifespans is a major
ethodological limitation of this analysis. If these teenagers went on
o live normal lifespans, the cost per year of life saved becomes
$200,000, even using the overall prices in this analysis. Finally, the
osts are based on yearly screening as used in Italy (1). A prior cost
nalysis, also based primarily on the Italian study but using a 1-time
creen, found a cost effectiveness of $76,100 per year of life saved for
he combination of history and physical and ECG, with the incre-
ental cost effectiveness of the ECG $42,900 (5), well within the
ocietally accepted range. While the optimum frequency of screening
s unknown, ECG screening programs performed at less frequent
ntervals have also saved lives (6). Biennial ECG screening has beenuggested as an alternative. Because the ECG increases sensitivity,
ther studies have found the addition of the ECG improves cost
ffectiveness over history and physical alone (7).
To recommend abandoning screening in favor of improving
esuscitation is not the best formula for progress. Screening linked
o research will refine our knowledge of the best application of the
ools available. Furthermore, population-based studies show that the
ate of survival from sudden cardiac arrest remains10% (8,9). While
e strongly support basic and clinical research into resuscitation, as
ell as community preparedness efforts (9), the combination of
revention and intervention offers more opportunities to save lives
han either alone, as has been suggested from analyses of coronary
eart disease deaths (10).
Rachel Lampert, MD
obert J. Myerburg, MD
Yale University School of Medicine
ection of Cardiology
89 Howard Avenue
ew Haven, Connecticut 06520
-mail: rachel.lampert@yale.edu
http://dx.doi.org/10.1016/j.jacc.2013.01.030
lease note: Dr. Lampert has received significant research grants from Medtronic,
oston Scientific, and St. Jude Medical, and modest honoraria from Medtronic (most
ecent fall 2011). Dr. Myerburg has reported that he has no relationships relevant to
he contents of this paper to disclose.
EFERENCES
1. Corrado D, Basso C, Pavei A, Michieli P, Schiavon M, Thiene G.
Trends in sudden cardiovascular death in young competitive athletes
after implementation of a preparticipation screening program. JAMA
2006;296:1593–601.
2. Halkin A, Steinvil A, Rosso R, Adler A, Rozovski U, Viskin S.
Preventing sudden death of athletes with electrocardiographic screen-
ing: what is the absolute benefit and how much will it cost? J Am Coll
Cardiol 2012;60:2271–6.
3. Maron BJ, Thompson PD, Ackerman MJ, et al. Recommendations
and considerations related to preparticipation screening for cardiovas-
cular abnormalities in competitive athletes: 2007 update: a scientific
statement from the American Heart Association Council on Nutri-
tion, Physical Activity, and Metabolism: endorsed by the American
College of Cardiology Foundation. Circulation 2007;115:1643–455.
4. Gersh BJ, Maron BJ, Bonow RO, et al. 2011 ACCF/AHA guideline
for the diagnosis and treatment of hypertrophic cardiomyopathy: a
report of the American College of Cardiology Foundation/American
Heart Association Task Force on Practice Guidelines. Developed in
collaboration with the American Association for Thoracic Surgery,
American Society of Echocardiography, American Society of Nuclear
Cardiology, Heart Failure Society of America, Heart Rhythm Society,
Society for Cardiovascular Angiography and Interventions, and Soci-
ety of Thoracic Surgeons. J Am Coll Cardiol 2011;58:e212–60.
5. Wheeler MT, Heidenreich PA, Froelicher VF, Hlatky MA, Ashley EA.
Cost-effectiveness of preparticipation screening for prevention of sudden
cardiac death in young athletes. Ann Intern Med 2010;152:276–86.
6. Tanaka Y, Yoshinaga M, Anan R, et al. Usefulness and cost effective-
ness of cardiovascular screening of young adolescents. Med Sci Sports
Exerc 2006;38:2–6.
7. Myerburg RJ, Vetter VL. Electrocardiograms should be included in
preparticipation screening of athletes. Circulation 2007;116:2616–26,
discussion 2626.
8. Rea TD, Eisenberg MS, Sinibaldi G, White RD. Incidence of
EMS-treated out-of-hospital cardiac arrest in the United States.
Resuscitation 2004;63:17–24.
9. Weisfeldt ML, Sitlani CM, Ornato JP, et al. Survival after application
of automatic external defibrillators before arrival of the emergency
medical system: evaluation in the resuscitation outcomes consortium
population of 21 million. J Am Coll Cardiol 2010;55:1713–20.
a
c
t
r
r
p
T
t
t
s
b
r
a
f
t
j
t
n
s
n
s
R
1554 Correspondence JACC Vol. 61, No. 14, 2013
April 9, 2013:1549–5410. Ford ES, Ajani UA, Croft JB, et al. Explaining the decrease in U.S. deaths
from coronary disease, 1980–2000. N Engl J Med 2007;356:2388–98.
Reply
We agree with the first 2 assertions made by Drs. Lampert and
Myerburg regarding our paper (1). First, cost projections in our
paper reflect on the entire screening process, not just electrocar-
diography (ECG) screening. Second, “prices” rather than “costs”
were presented and we alluded to that distinction in our paper (1).
Our model presents not only the “number needed to screen,” but
also the partition of secondary tests (mainly driven by an abnormal
ECG) that are necessary to save 1 life. One may enter any price
deemed “appropriate” and calculate a new cost per life saved.
Obviously, all these cost projections assume that the data reported
in Italy by Corrado et al. (2) are not only correct, but are also
applicable to other societies.
We used cost per life saved rather than “costs per life-year
saved” (1). However, assuming that all athletes with hypertrophic
cardiomyopathy will have a normal lifespan if only identified
through screening but would die otherwise is unsubstantiated. It is
also incorrect to use Wheeler et al.’s cost-effectiveness analysis (3)
s a standard for comparison. Wheeler et al. (3) also based their
alculations on the Italian study by Corrado et al. (2) and credited
he number of lives saved to ECG screening but dramatically
educed cost calculations by ignoring that ECG screening was
epeated 20 times during the study period.
Lampert and Myerburg argue that ECG screening programs
erformed less frequently “have also saved lives,” citing a study by
anaka et al. (4). However, Tanaka et al. (4) never demonstrated
hat athletes’ lives are actually saved by ECG screening. Instead,
hey reported the incidence of sudden death among 37,000 high
chool students undergoing ECG screening at 3-year intervals: 3
oys died suddenly during follow-up, representing a sudden-death
ate of 1.32 in 100,000/year. Importantly, 2 of the 3 calamities had
normal ECG and were actually missed by screening. The third
atality was disqualified from competitive sports because of hyper-
rophic cardiomyopathy, only to die suddenly, years later, while
ogging on his own. The latter case in point is a poignant reminder
hat disqualification of afflicted athletes from organized sports will
ot always translate into normal longevity. True, 8 additional
tudents were identified as high-risk individuals (6 of them were
ot athletes). It is appropriate to conclude from the Tanaka et al.
tudy that systematic ECG screening of high-school students mayidentify high-risk characteristics in 1:4,200 adolescents (9 in
37,807). However, counting all identified high-risk individuals as
“lives saved” would be grossly erroneous.
We never advocated abandoning screening but we do object to
the concept of mandatory ECG screening of athletes because the
benefit of ECG-screening for the prevention of sudden death in
athletes remains unproven. Proponents of ECG screening must
accept that the level of evidence supporting such a strategy has not
reached the stage that justifies making this test mandatory. We
simply do not know enough about the natural history of many
conditions identified by screening to provide an accurate esti-
mation of risk. We should not compel athletes to undergo
unsolicited tests when all too often we do not know what to do
with the results (5).
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